Figure 6From: Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study Number of reflux episodes over a period of 24 h. Estimation using a mixed-effect Emax model of (A), the predicted exposure–response curve with 95% CI curves (intersection of efficacy and pharmacokinetics analysis set) and (B), the dose–response curve with 95% CIs (efficacy analysis set) for lesogaberan. CI, confidence interval.Back to article page